If Only They Hadn't Said Anything | GenomeWeb

Roche's approach to buying Illumina may have cost the Swiss drug development and diagnostic firm a chance at the San Diego-based next-generation sequencing firm, Illumina President and CEO Jay Flatley tells Bloomberg.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.